However, no study has yet examined plasma and tumor levels of VEGF in the human, and in a retrospective subset analysis, pretreatment tumor mRNA levels or plasma protein levels of VEGF did not correlate with benefit from the addition of bevacizumab to standard chemotherapy in pancreatic or colorectal cancer [43,44]. This evidence concerns the gene VEGFA and neoplasm.